Relationship of Advanced Holding Education and ADherence on Antithrombotic in Younger SPAF Patients
Latest Information Update: 25 Sep 2024
Price :
$35 *
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Thromboembolism
- Focus Therapeutic Use
- Acronyms ReAHEAD
- Sponsors Boehringer Ingelheim
- 23 May 2023 Status changed from active, no longer recruiting to completed.
- 08 May 2023 Planned End Date changed from 1 Sep 2023 to 8 May 2023.
- 08 May 2023 Planned primary completion date changed from 30 Apr 2023 to 8 May 2023.